2 A significant issue is that only 10 mg, rather than the 30 mg often administered thrice weekly, demonstrated clinical efficacy with low toxicity. On the other hand, 5-8 weeks of alemtuzumab therapy was needed for improvement of the AIHA, instead of 3-5 weeks noted in our report published in Leukemia January 2007. Median treatment duration was 12 weeks compared to the 5 weeks in our report, and yet the AIHA response duration was 9-26 months.
Reply to 'Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia' by Dr Laurenti et al. 1 published in Leukemia, which describes three patients with CLL-associated autoimmune hemolytic anemia (AIHA) responding after alemtuzumab therapy. These results substantiate our own observations. 2 A significant issue is that only 10 mg, rather than the 30 mg often administered thrice weekly, demonstrated clinical efficacy with low toxicity. On the other hand, 5-8 weeks of alemtuzumab therapy was needed for improvement of the AIHA, instead of 3-5 weeks noted in our report published in Leukemia January 2007. Median treatment duration was 12 weeks compared to the 5 weeks in our report, and yet the AIHA response duration was 9-26 months.
We do not know the optimal dose of alemtuzumab, but Dr Hale reported in 2004 3 that it takes a longer time to detect alemtuzumab in serum after subcutaneous delivery compared to intravenous administration. Lower dose of alemtuzumab should perhaps be administered over a protracted period to maximize efficacy and ameliorate toxicity.
